Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 55-98-1
Drug Levels and Effects
Summary of Use during Lactation
Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy.[1] It might be possible to breastfeed safely with busulfan during intermittent therapy with an appropriate period of breastfeeding abstinence. Although minimal data are available to determine an appropriate period to withhold breastfeeding, the drug's terminal half-live of 2.5 hours suggests that at least 24 hours may be sufficient. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk.[2] Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant.[3]
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Busulfan in a dosage of 4 mg daily for 5 weeks was taken for myeloid leukemia by one woman while breastfeeding. Weekly monitoring found no adverse effects on her infant's leukocyte count or hemoglobin.[4]
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
- Pistilli B, Bellettini G, Giovannetti E, et al. Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: How should we counsel cancer patients about breastfeeding? Cancer Treat Rev. 2013;39:207–11. [PubMed: 23199900]
- 2.
- Urbaniak C, McMillan A, Angelini M, et al. Effect of chemotherapy on the microbiota and metabolome of human milk, a case report. Microbiome. 2014;2:24. [PMC free article: PMC4109383] [PubMed: 25061513]
- 3.
- Stopenski S, Aslam A, Zhang X, et al. After chemotherapy treatment for maternal cancer during pregnancy, is breastfeeding possible? Breastfeed Med. 2017;12:91–7. [PubMed: 28170295]
- 4.
- Bounameaux Y, Durenne JM. Ann Soc Belge Med Trop. 1964;44:381–3. [A case of leukemia in a lactating female: effect of treatment with busulfan on the infant] [PubMed: 14259241]
Substance Identification
Substance Name
Busulfan
CAS Registry Number
55-98-1
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PMCPubMed Central citations
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- Review Bleomycin.[Drugs and Lactation Database (...]Review Bleomycin.. Drugs and Lactation Database (LactMed®). 2006
- Review Dacarbazine.[Drugs and Lactation Database (...]Review Dacarbazine.. Drugs and Lactation Database (LactMed®). 2006
- Review Thioguanine.[Drugs and Lactation Database (...]Review Thioguanine.. Drugs and Lactation Database (LactMed®). 2006
- Review Azacitidine.[Drugs and Lactation Database (...]Review Azacitidine.. Drugs and Lactation Database (LactMed®). 2006
- Review Hydroxyurea.[Drugs and Lactation Database (...]Review Hydroxyurea.. Drugs and Lactation Database (LactMed®). 2006
- Busulfan - Drugs and Lactation Database (LactMed®)Busulfan - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...